This provider is a retina specialist whose Medicare billing is heavily driven by intravitreal biologic injections and associated ophthalmology services, reflecting a clinic-based retina practice that treats retinal vascular and neovascular conditions; the top procedure by revenue is J0178 (aflibercept) with $917.6K and substantial volumes reported. Revenue concentration is high: the precomputed top three Medicare codes account for 66.8% of this provider's total Medicare revenue, indicating the practice depends primarily on a small set of high-cost injection drugs for its Medicare reimbursement. The provider’s total Medicare revenue of $2.4M contrasts with no Medicaid billing on file, so the payer mix is effectively single-payer Medicare — Medicaid is absent from reported activity and therefore not a revenue source for this NPI. Competitive standing on key drug codes is mixed: J0178 ranks #957 of 3204 providers nationally (70th percentile), J2777 ranks #844 of 2039 (58th percentile), and J2778 ranks #275 of 1208 (77th percentile), suggesting typical to above-typical participation in high-cost intravitreal biologics but not national dominance. Several non-drug ophthalmology services show above-typical volumes: 92012 ranks in the 99th percentile (described as an "extreme outlier") and 92134 is in the 96th percentile ("notably above typical national volume"), suggesting a heavier-than-average mix of established patient visits and retinal imaging consistent with ongoing management of chronic retinal disease. The provider has long tenure on file, with NPI enumeration dated 2006-02-10 (~20 years ago), indicating an established practice presence in New Brunswick, NJ that likely maintains stable referral and follow-up patterns. There are a few mid-range and lower-volume miscellaneous codes (J3590, Q5128, J3490, J7999) with modest revenue shares (single-digit percentages) and typical national percentiles, indicating occasional use of unclassified or biosimilar products and compounded drugs but not as major revenue drivers. Procedural codes for injections as separate procedures (67028) and comprehensive/established eye exams (92014, 92012) together contribute meaningful revenue, reflecting a care model that combines in-office pharmacologic therapy with routine ophthalmic evaluation and imaging rather than exclusively procedure-focused practice. Overall the profile describes a Medicare-focused retina specialist practice with concentrated revenue from anti-VEGF and related biologic injections, high utilization of follow-up visits and retinal imaging, and no recorded Medicaid activity to diversify payer exposure.